



## Padcev® (enfortumab vedotin-ejfv) – Expanded indication

- On July 9, 2021, Seagen and Astellas Pharma announced the regular FDA approval and expanded indication for Padcev (enfortumab vedotin-ejfv), for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who:
  - Have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or
  - Are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.
- Padcev was previously approved via accelerated approval for the treatment of adult patients with locally advanced or mUC who have previously received a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
- The FDA decision to convert accelerated approval to regular approval was based on data from EV-301, an open-label, randomized study in 608 patients with locally advanced or mUC who received prior treatment with a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy. Patients were randomized to receive Padcev on days 1, 8 and 15 of a 28-day cycle or investigator's choice of chemotherapy. The major efficacy measures were overall survival (OS), progression free survival (PFS), and overall response rate (ORR).
  - Median OS was 12.9 months and 9.0 months for Padcev and chemotherapy, respectfully (hazard ratio [HR] 0.70, 95% CI: 0.56, 0.89;  $p = 0.0014$ ).
  - Median PFS was 5.6 months and 3.7 months for Padcev and chemotherapy, respectfully (HR 0.62, 95% CI: 0.51, 0.75;  $p < 0.0001$ ).
  - ORR was 40.6% and 17.9% for Padcev and chemotherapy, respectfully ( $p < 0.0001$ ).
- Additionally, the efficacy of Padcev was evaluated in Cohort 2 of EV-201, a single-arm, multi-cohort study in 89 patients with locally advanced or mUC who received prior treatment with a PD-1 or PD-L1 inhibitor, and were cisplatin ineligible and did not receive platinum in the locally advanced or metastatic setting.
  - ORR was 51% (95% CI: 39.8, 61.3). Median duration of response was 13.8 months (95% CI: 6.4, not estimable).
- The recommended dose of Padcev is 1.25 mg/kg (up to a maximum of 125 mg for patients  $\geq 100$  kg) administered as an intravenous infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.